Skip to main content

Table 1 Patient demographics

From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Characteristics

Specification

Value (%)

Age, years

Mean ± Std

51.0 ± 9.3

Min~Max

28.1.70.1

Gender

Male

21 (58.3)

Female

15 (41.7)

Tumor histology

Melanoma

22 (61.1)

Urothelial carcinoma

8 (22.2)

Renal cell carcinoma

6 (16.7)

ECOG PS

0

16 (44.4)

1

20 (55.6)

PD-L1 expression*

Positive

16 (44.4)

Negative

12 (33.3)

NA

8 (22.2)

Prior therapies

Chemotherapy

36 (100.0)

Surgery

34 (94.4)

Radiation therapy

7 (19.4)

  1. Age, gender, histology, ECOG performance score, PD-L1 expression on tumor biopsy by IHC staining, and prior therapies were summarized. *PD-L-positive status was defined as the presence of membrane staining of any intensity in ≥ 1% of tumor cells